AgomAb Therapeutics NV

AGMB chart

AgomAb Therapeutics NV news

• Form 4 AgomAb Therapeutics NV: David R. Epstein (Director) For: 5 November

  Investing.com Nigeria · Nov 7, 4:49 AM EST

• Director David Epstein Buys 15,000 Shares of AgomAb Therapeutics NV (AGMB)

  GuruFocus · Nov 6, 12:49 PM EST

• Three purchases at $6.81–$6.98 add 15,000 shares for an AgomAb Therapeutics (AGMB) director.

  Stock Titan · Nov 6, 6:39 AM EST

• AgomAb Therapeutics NV AGMB Stock Forecast & Price Target

  Yahoo! Finance Canada · Nov 6, 3:00 AM EST

• Agomab to Participate in Upcoming Investor Conferences

  Yahoo Finance · Nov 4, 4:05 PM EST

• Agomab's upcoming conference appearances span Boston, London, Miami and New York.

  Stock Titan · Nov 4, 4:05 PM EST

• Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease

  Yahoo Finance · Oct 13, 4:05 PM EDT

• Agomab to Present STENOVA Open-Label Extension Data of Ontunisertib at UEG Week 2026 and Host Scientific Symposium on Fibro-Inflammation

  Yahoo Finance · Oct 8, 4:05 PM EDT

• Agomab stock jumps on positive trial data

  Yahoo Finance · Oct 1, 9:27 AM EDT

• Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn's Disease

  Yahoo Finance · Oct 1, 6:30 AM EDT

• Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study

  Yahoo Finance · Sep 14, 4:05 PM EDT

• Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors

  Yahoo Finance · Sep 11, 4:05 PM EDT

AgomAb Therapeutics NV key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 6-KFORM 6-K2026-10-13
• 6-KFORM 6-K2026-10-01
• 6-KFORM 6-K2026-09-14
• 6-KFORM 6-K2026-09-11
• 6-KFORM 6-K2026-08-10
• 6-K6-K2026-08-06
• 6-KFORM 6-K2026-06-23
• 6-KFORM 6-K2026-05-27
• 6-KFORM 6-K2026-04-24
• 20-FFORM 20-F2026-04-23
• 6-KFORM 6-K2026-03-05
• 6-KFORM 6-K2026-02-09

About AgomAb Therapeutics NV

Ticker

AGMB (Nasdaq)

Industry

Biological Products, (No Diagnostic Substances)

Headquarters

Antwerpen

Incorporated in

Belgium

Fiscal year end

December 31

SEC CIK

2020932

Frequently asked questions